A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores

被引：0

作者：

Takeo Fujii

Hiroko Masuda

Yee Chung Cheng

Fei Yang

Aysegul A. Sahin

Yasuto Naoi

Yuki Matsunaga

Akshara Raghavendra

Arup Kumar Sinha

Jose Rodrigo Espinosa Fernandez

Anjali James

Keisuke Yamagishi

Tomoko Matsushima

Robert Schuetz

Debu Tripathy

Sachiyo Tada

Rubie S. Jackson

Shinzaburo Noguchi

Seigo Nakamura

Jared D. Acoba

Naoto T. Ueno

机构：

[1] The University of Texas MD Anderson Cancer Center,Department of Breast Medical Oncology

[2] The University of Texas MD Anderson Cancer Center,Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, Unit 1354

[3] University of Hawai’i,John A. Burns School of Medicine

[4] University of Hawai’i Cancer Center,Department of Breast Surgical Oncology

[5] Showa University,Division of Hematology and Oncology

[6] Medical College of Wisconsin,Department of Translational Molecular Pathology

[7] The University of Texas MD Anderson Cancer Center,Department of Pathology

[8] The University of Texas MD Anderson Cancer Center,Department of Breast and Endocrine Surgery

[9] Osaka University Graduate School of Medicine,Anne Arundel Medical Center

[10] Sysmex Corporation,undefined

[11] Rebecca Fortney Breast Center,undefined

[12] Hyogo Prefectural Nishinomiya Hospital,undefined

来源：

Breast Cancer Research and Treatment | 2021年 / 189卷

关键词：

Breast cancer; 21-gene signature assay; 95-gene signature assay; Estrogen receptor-positive; Recurrence Score;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：455 / 461

页数：6

共 50 条

[21] Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer
Yunan Han
Zhi-Feng Miao
Min Lian
Lindsay L. Peterson
Graham A. Colditz
Ying Liu
Breast Cancer Research and Treatment, 2020, 184 : 915 - 925
[22] Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
Bernhard C. Pestalozzi
Christoph Tausch
Konstantin J. Dedes
Christoph Rochlitz
Stefan Zimmermann
Roger von Moos
Ralph Winterhalder
Thomas Ruhstaller
Andreas Mueller
Katharina Buser
Markus Borner
Urban Novak
Catrina Uhlmann Nussbaum
Bettina Seifert
Martin Bigler
Vincent Bize
Simona Berardi Vilei
Christoph Rageth
Stefan Aebi
BMC Cancer, 17
[23] The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis
Weiser, Roi
Haque, Waqar
Polychronopoulou, Efstathia
Hatch, Sandra S.
Kuo, Yong-fang
Gradishar, William J.
Klimberg, V. Suzanne
BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (03) : 667 - 676
[24] Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
Pestalozzi, Bernhard C.
Tausch, Christoph
Dedes, Konstantin J.
Rochlitz, Christoph
Zimmermann, Stefan
von Moos, Roger
Winterhalder, Ralph
Ruhstaller, Thomas
Mueller, Andreas
Buser, Katharina
Borner, Markus
Novak, Urban
Nussbaum, Catrina Uhlmann
Seifert, Bettina
Bigler, Martin
Bize, Vincent
Vilei, Simona Berardi
Rageth, Christoph
Aebi, Stefan
BMC CANCER, 2017, 17
[25] The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis
Roi Weiser
Waqar Haque
Efstathia Polychronopoulou
Sandra S. Hatch
Yong-fang Kuo
William J. Gradishar
V. Suzanne Klimberg
Breast Cancer Research and Treatment, 2021, 185 : 667 - 676
[26] Predictive value of 21-gene recurrence score assay in non-estrogen receptor-positive and lymph node-negative breast cancer
Lu, Kai
Li, Hui
Wu, Zhaoshu
Liu, Dong
Ye, Hongling
Xu, Liang
Liu, Yanwen
JOURNAL OF BUON, 2018, 23 (05): : 1297 - 1301
[27] Validation of the prognosis of patients with ER-positive, HER2-negative and node-negative invasive breast cancer classified as low risk by Curebest™ 95GC Breast in a multi-institutional registry study
Naoi, Yasuto
Tsunashima, Ryo
Shimazu, Kenzo
Oikawa, Masahiro
Imanishi, Seiichi
Koyama, Hiroshi
Kamada, Yoshihiko
Ishihara, Kazuhiro
Suzuki, Masahiko
Osako, Tomo
Kinoshita, Takayuki
Suto, Akihiko
Nakamura, Seigo
Tsuda, Hitoshi
Noguchi, Shinzaburo
ONCOLOGY LETTERS, 2023, 25 (05)
[28] Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study
Llombart-Cussac, Antonio
Anton-Torres, Antonio
Rojas, Beatriz
Andres, Raquel
Martinez, Noelia
Rodriguez, Cesar A.
Marin, Sara
Puertolas, Teresa
Gonzalez, Alejandro Falcon
Fernandez-Murga, Maria Leonor
Hagen, Carlos
Ruiz-Borrego, Manuel
CANCERS, 2023, 15 (05)
[29] Impact of the 21-gene recurrence score assay in adjuvant chemotherapy selection for node-negative, hormone receptor-positive breast cancer in the Chinese population
Zhang, Y. N.
Zhou, Y. D.
Mao, F.
Sun, Q.
NEOPLASMA, 2015, 62 (04) : 658 - 665
[30] Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?
Lamond, Nathan W. D.
Skedgel, Chris
Younis, Tallal
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (02) : 243 - 250

← 1 2 3 4 5 →